<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023656</url>
  </required_header>
  <id_info>
    <org_study_id>1611HJKim808</org_study_id>
    <nct_id>NCT04023656</nct_id>
  </id_info>
  <brief_title>Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea</brief_title>
  <official_title>Prognosis of Paroxysmal Kinesigenic Choreoathetosis in Korea: a Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the prognosis of paroxysmal kinesigenic choreoathetosis
      (PKC) in Korean.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PKC is a hyperkinetic movement disorder including dystonia, chorea, athetosis, or ballism,
      which are characteristically triggered by a sudden movement from rest. The prevalence of this
      disorder is estimated to be 1 in 150,000 population. Males are more commonly affected than
      females, and the age of onset is typically in childhood or adolescence. PKC is mainly a
      familial disorder with autosomal dominant inheritance and incomplete penetrance, but it can
      occur sporadically. The PRRT2 (proline-rich transmembrane protein 2) gene is believed to be
      the major causative gene.

      The prognosis of PKC is usually favorable. The severity and frequency of the attacks are
      reduced by anticonvulsant medication such as carbamazepine, and the number of the attacks
      decreases at the age of 20-30 years. However, there has been little study of long-term
      prognosis of PKC, and no study has been conducted in Korean population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Changes in clinical characteristics of PKC relative to the baseline.</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Improvement or worsening of the attacks relative to the baseline state assessed by a questionnaire, categorized as following; 1, full remission (absence of the attacks); 2, improvement (more than 50% decreased mean frequency of the attacks); 3, worsening (increased frequency of the attacks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clinical characteristics of PKC over the last year.</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Improvement or worsening of the attacks over the last year assessed by a questionnaire, categorized as following; 1, full remission (absence of the attacks); 2, improvement (more than 50% decreased mean frequency of the attacks); 3, worsening (increased frequency of the attacks).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in medication history of PKC over the last year.</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Continuation or discontinuation of the medication for relief of the attacks assessed by a questionnaire, categorized as following; 1, continuation of medication; 2, discontinuation of medication.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Paroxysmal Kinesigenic Choreoathetosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators enrolled subjects at the Seoul National University Hospital. Subjects
        were diagnosed with paroxysmal kinesigenic choreoathetosis (PKC) and followed-up at the
        Seoul National University Hospital. All subjects were enrolled voluntarily and understood
        the contents of this trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female PKC patients who were18 years of age and older

          -  Subjects were diagnosed as paroxysmal kinesigenic choreoathetosis (PKC)

          -  Subjects were enrolled voluntarily and understood the contents of this trial

        Exclusion Criteria:

          -  Existence of lesions on the brain

          -  Existence of neurological deficit that suspected lesions on the brain

          -  Existence of epileptiform discharges on electroencephalogram

          -  Subjects with secondary PKC which was caused by other disorder or illness

          -  Existence of illness or problems which made difficult to be enrolled to this trial
             judged by clinicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han-joon Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han-joon Kim, MD, Ph.D</last_name>
    <phone>+82-2-2072-1219</phone>
    <email>movement@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han-joon Kim, MD, Ph.D</last_name>
      <phone>+82-2-2072-1219</phone>
      <email>movement@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Han-joon Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Mao CY, Shi CH, Song B, Wu J, Ji Y, Qin J, Li YS, Wang JJ, Shang DD, Sun SL, Xu YM. Genotype-phenotype correlation in a cohort of paroxysmal kinesigenic dyskinesia cases. J Neurol Sci. 2014 May 15;340(1-2):91-3. doi: 10.1016/j.jns.2014.02.034. Epub 2014 Mar 3.</citation>
    <PMID>24661410</PMID>
  </reference>
  <reference>
    <citation>Li HF, Chen WJ, Ni W, Wang KY, Liu GL, Wang N, Xiong ZQ, Xu J, Wu ZY. PRRT2 mutation correlated with phenotype of paroxysmal kinesigenic dyskinesia and drug response. Neurology. 2013 Apr 16;80(16):1534-5. doi: 10.1212/WNL.0b013e31828cf7e1. Epub 2013 Mar 27.</citation>
    <PMID>23535490</PMID>
  </reference>
  <reference>
    <citation>Castiglioni C, López I, Riant F, Bertini E, Terracciano A. PRRT2 mutation causes paroxysmal kinesigenic dyskinesia and hemiplegic migraine in monozygotic twins. Eur J Paediatr Neurol. 2013 May;17(3):254-8. doi: 10.1016/j.ejpn.2012.10.010. Epub 2012 Nov 19.</citation>
    <PMID>23182655</PMID>
  </reference>
  <reference>
    <citation>Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain. 2015 Dec;138(Pt 12):3476-95. doi: 10.1093/brain/awv317. Epub 2015 Nov 23. Review.</citation>
    <PMID>26598493</PMID>
  </reference>
  <reference>
    <citation>Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, Lynch DR, Mathews KD, Swoboda KJ, Harris J, Soong BW, Ashizawa T, Jankovic J, Renner D, Fu YH, Ptacek LJ. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004 Dec 28;63(12):2280-7. Review.</citation>
    <PMID>15623687</PMID>
  </reference>
  <reference>
    <citation>Unterberger I, Trinka E. Diagnosis and treatment of paroxysmal dyskinesias revisited. Ther Adv Neurol Disord. 2008 Sep;1(2):4-11. doi: 10.1177/1756285608095119.</citation>
    <PMID>21180566</PMID>
  </reference>
  <reference>
    <citation>Bennett LB, Roach ES, Bowcock AM. A locus for paroxysmal kinesigenic dyskinesia maps to human chromosome 16. Neurology. 2000 Jan 11;54(1):125-30.</citation>
    <PMID>10636137</PMID>
  </reference>
  <reference>
    <citation>Gardiner AR, Jaffer F, Dale RC, Labrum R, Erro R, Meyer E, Xiromerisiou G, Stamelou M, Walker M, Kullmann D, Warner T, Jarman P, Hanna M, Kurian MA, Bhatia KP, Houlden H. The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain. 2015 Dec;138(Pt 12):3567-80. doi: 10.1093/brain/awv310. Epub 2015 Nov 23. Review.</citation>
    <PMID>26598494</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Soong B, McKenna C, Brunt ER, Litt M, Bale JF Jr, Ashizawa T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann PT, Nespeca MP, Jankovic J, Leppert M, Ptácek LJ. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology. 2000 Jul 25;55(2):224-30.</citation>
    <PMID>10908896</PMID>
  </reference>
  <reference>
    <citation>Méneret A, Grabli D, Depienne C, Gaudebout C, Picard F, Dürr A, Lagroua I, Bouteiller D, Mignot C, Doummar D, Anheim M, Tranchant C, Burbaud P, Jedynak CP, Gras D, Steschenko D, Devos D, Billette de Villemeur T, Vidailhet M, Brice A, Roze E. PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology. 2012 Jul 10;79(2):170-4. doi: 10.1212/WNL.0b013e31825f06c3. Epub 2012 Jun 27.</citation>
    <PMID>22744660</PMID>
  </reference>
  <reference>
    <citation>Marini C, Conti V, Mei D, Battaglia D, Lettori D, Losito E, Bruccini G, Tortorella G, Guerrini R. PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine. Neurology. 2012 Nov 20;79(21):2109-14. doi: 10.1212/WNL.0b013e3182752ca2. Epub 2012 Oct 17.</citation>
    <PMID>23077026</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Han-Joon Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>paroxysmal kinesigenic choreoathetosis</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Korean population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Basal Ganglia Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

